We first evaluated the specificity of 89Zr-trastuzumab in both HER2+ and Src-active breast cancer cell lines, BT-474 and JIMT-1, which are trastuzumab-sensitive and trastuzumab-resistant, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.